Pharma share price

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. Key Executives • Mr. Justin D. Gover (Age 50) CEO & Exec. Director Comp: $1.19M • Mr. Scott M. Giacobello (Age 51) Chief Financial Officer Comp: $743.33k • Mr. Douglas B. Snyder (Age 57) Chief Legal Officer & Sec. Comp: $787.02k • Dr. Volker Knappertz M.D. (Age 56) D.Sc., Chief Medical Officer Comp: $830.47k • Mr. Christopher John Tovey (Age 56) Chief Operating Officer • Kristen Cardillo VP of Corp. Communication • Ms. Tina St. Leger Chief HR Officer • Prof. Ben Whalley Head of Discovery Research • Mr. Darren S. Cline (Age 57) U.S. Chief Commercial Officer More Executives GW Pharmaceuticals plc (NASDAQ:GWPH) announced its quarterly earnings dat...

The company has consistently outperformed the industry primarily on account of strong volume growth, JPMorgan said as it believes the company will continue to gain market share. Also Read: Hero MotoCorp share price falls amid mixed brokerage reactions; should you buy, sell or hold? Mankind Pharma shares have delivered 37% returns since its listing in May 2023, JPMorgan highlighted and forecasts revenue and earnings CAGR of 15% and 22%, respectively, over FY23-26. Meanwhile, Nirmal Bang also initiated coverage on the pharmaceutical company with an “Accumulate" rating and a target price of ₹1,440 per share. Nirmal Bang said Mankind Pharma is largely a pure-play domestic story. The domestic market’s contribution is also the highest among the large cap domestic pharma peers, which gives it greater revenue visibility against the backdrop of uncertain export growth, especially in the generic segment. Also Read: MRF becomes the first Indian stock to touch ₹1 lakh per share mark It expects revenue, EBITDA and PAT CAGR of 13.4%, 22.4% and 26.8%, respectively, over FY23-FY25 with margin improvement of 360 bps. “Future growth strategy will revolve around Increased covered market presence, especially in the Chronic segment, gaining scale in the Consumer Health business, increasing penetration in Metro and Class-I cities and increasing doctor engagements, especially the specialists," Nirmal Bang said. On May 9, ₹1,300 per equity share on the BSE as compred to the IPO price of ₹1,080 pe...

June 12 (Reuters) - Novartis Seattle-based Chinook's shareholders will receive $3.2 billion, or $40 per share, in cash under the agreed deal, plus a contingent value right worth up to $300 million, depending on certain regulatory achievements, Novartis said on Monday. The upfront payment represents a premium of 66.7% to Chinook's Friday closing price. Chinook's shares were at $40.1 in premarket trading on Monday. Novartis CEO Vas Narasimhan is eager to raise the prospect of future blockbuster drugs after leading a push to slash costs and reshape the Swiss drugmaker to focus on fewer therapeutic areas and the most promising geographic markets. Chinook, whose shares closed at $23.99 on Friday, has a leading compound designed to treat IgA Nephrophathy, or IgAN, a rare disease that can lead to kidney failure in young adults which has attracted a range of developers and is already the target of drug candidate developed by Novartis. Narasimham has previously said he would look primarily at deal targets worth less than $5 billion. The transaction is expected to close in the second half of 2023, Novartis said in a statement. Chinook expects to see the pivotal readout in the fourth quarter of this year of a clinical trial in the third and last stage of development of oral drug candidate atrasentan to treat IgAN. Chinook is also working on zigakibart, another experimental IgAN treatment that is injected, and plans to start a Phase 3 trial in the third quarter of 2023. Narasimhan sco...

P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public. Public Float The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. Dividend Yield A company's dividend expressed as a percentage of its current stock price. Key Stock Data • Shares Sold Short The total number of shares of a security that have been sold short and not yet repurchased. Change from Last Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. P...